Hajar Abu Alrob

Hajar Abu Alrob

Auto-generated profile, based on publicly available information

Hajar Abu Alrob

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
ANAhmed M Negm
Ahmed M Negm
CKCourtney C. Kennedy
Courtney C. Kennedy
LTLehana Thabane
Lehana Thabane
AVAreti-Angeliki Veroniki
Areti-Angeliki Veroniki
JAJonathan Derrick Adachi
Jonathan Derrick Adachi
APAlexandra Papaioannou
Alexandra Papaioannou

17 February 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
DADalal Ali
Dalal Ali
TCThomas Carpenter
Thomas Carpenter
EIErik A Imel
Erik A Imel
LWLeanne M Ward
Leanne M Ward
NANatasha M. Appelman-Dijkstra
Natasha M. Appelman-Dijkstra
AKAliya A. Khan
Aliya A. Khan
Context: An International Working Group (IWG) developed new guidelines on the diagnosis, evaluation, management, and monitoring of X-linked hypophosphatemia (XLH) in children. Over the past 5 years, important advances have occurred in our understanding of the presentation, complications, and treatment of XLH. Methods: A group of 50 international experts in XLH from Canada, the United States, Europe, Asia, and South America, along with methodology experts and a patient partner, held 18 teleconference meetings in 2023-2024. These meetings addressed key issues regarding diagnosing, evaluating, managing, and monitoring XLH in children. Two systematic reviews were conducted to examine the impact of burosumab compared to conventional therapy (phosphate salts and active vitamin D) or no therapy, and to assess the impact of conventional therapy vs no therapy on patient-important outcomes. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Additionally, narrative reviews were completed on XLH diagnosis and the role of genetic testing, and an expert clinical practice survey informed the monitoring recommendations. Outcomes: An approach to establishing the diagnosis of XLH is presented. GRADEd recommendations were developed on treatment strategies for XLH in children. Monitoring recommendations, GRADEd as weak with very low certainty, were based on clinical practice survey of the IWG experts. The guidelines also addressed dental complications and proposed potential strategies to mitigate them. Conclusion: These clinical practice guidelines provide an update of the current evidence on the diagnosis and management of XLH and provide a comprehensive guidance for multidisciplinary healthcare professionals involved in the care of children with XLH.

17 April 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
AKAliya A. Khan
Aliya A. Khan
DADalal Ali
Dalal Ali
NANatasha M. Appelman-Dijkstra
Natasha M. Appelman-Dijkstra
TCThomas Carpenter
Thomas Carpenter
CCCatherine Chaussain
Catherine Chaussain
Maria Luisa BrandiMaria Luisa Brandi
Maria Luisa Brandi
Purpose: An international working group (IWG) consisting of experts in X-linked hypophosphatemia (XLH) developed global guidelines providing a comprehensive, evidence-based approach to XLH diagnosis, management, and monitoring. Methods: The IWG, consisting of 43 members as well as methodologists and a patient partner, conducted 2 systematic reviews (SRs) and narrative reviews to address key areas. The SRs addressed the impact of burosumab compared to conventional therapy (phosphate and active vitamin D) or no therapy on patient-important outcomes in adults. They also evaluated conventional therapy compared to no therapy. GRADE methodology was applied to evaluate the certainty of evidence. Non-GRADED recommendations were made in the presence of insufficient evidence to conduct SRs. These guidelines have been reviewed and endorsed by several medical and patient societies and organizations. Results: The diagnosis of XLH is based on integrating clinical evaluation, laboratory findings confirming renal phosphate wasting (following exclusion of conditions mimicking XLH), and skeletal imaging. Fibroblast growth factor 23 measurement and DNA analysis are of value in the diagnosis, if available. Pathogenic or likely pathogenic variants in the PHEX gene are confirmatory but not necessary for the diagnosis. Management requires a multidisciplinary team knowledgeable and experienced in XLH. Effective medical therapy with burosumab can improve fracture and pseudofracture healing. Main Conclusion: In adults with XLH and fractures or pseudofractures, burosumab is recommended over no therapy (strong recommendation, GRADEd). Additionally, burosumab is suggested as the preferred treatment compared to conventional therapy (conditional recommendation, GRADEd) in the absence of fractures or pseudofractures. If burosumab is not available, symptomatic adults should be treated with conventional therapy (Non-GRADEd recommendation).

22 April 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
HAHajar AbuAlrob
Hajar AbuAlrob
VAVehra Muhammad Afeef
Vehra Muhammad Afeef
ASAbdallah Shurman
Abdallah Shurman
ASAlexandra Shulkin
Alexandra Shulkin
AAAshlee Azizudin
Ashlee Azizudin
APAlexandra Papaioannou
Alexandra Papaioannou
Objectives This review summarises the impact of hip fractures on health outcomes including subsequent falls, hospitalisation, length of hospital stay (LOS), functional status, quality of life and mortality in older adults with cognitive impairment or dementia. It also explores the risk of institutionalisation following a hip fracture in this population. Design A scoping review following the Arksey and O’Malley framework guided by the Joanna Briggs Institute methodology and adheres to Preferred Reporting Items for Systematic Reviews and Meta-analyses extension for Scoping Reviews guidelines. Data sources A comprehensive search strategy was developed to search MEDLINE, EMBASE, CINAHL and grey literature, with additional references identified through citation searching and Web of Science. Eligibility criteria Studies were included if they examined older adults with cognitive impairment or dementia who experienced a hip fracture and reported outcomes related to hospitalisation, functional status, quality of life, mortality or institutionalisation. Data extraction and synthesis Study selection and data extraction were conducted independently by two reviewers using Covidence software. A narrative synthesis approach was employed to summarise findings and identify key themes, patterns and gaps in the literature. Results We identified 30 studies reporting health outcomes following hip fracture. Overall, the studies indicated that individuals with cognitive impairment or dementia have higher hospitalisation rates, poorer walking ability and functional outcomes, as well as reduced quality of life posthip fracture. The LOS for individuals with dementia following hip fracture was inconsistent across studies, with some reporting shorter LOS and others indicating longer LOS. Individuals with dementia consistently exhibit higher mortality rates at 30 days, 90 days and 1-year postfracture compared with those without dementia. We found 21 studies that evaluated the risk of institutionalisation following a hip fracture. Older adults with dementia were significantly more likely to be institutionalised posthip fracture, with nearly five times the risk of failing to return home compared with those without dementia. This increased risk persists up to 1-year postfracture and is particularly pronounced in those with severe cognitive impairment, with higher rates of nursing home placement observed among individuals with hip fractures. Conclusion Older adults with cognitive impairment or dementia experience significantly worse outcomes following hip fractures, including higher mortality, poorer functional outcomes, reduced quality of life and a higher risk of institutionalisation postfracture. Future research should focus on developing effective strategies for fracture prevention, including optimising osteoporosis treatment in this high-risk population, and developing targeted interventions to improve the impact of fractures on functional outcomes and reduce institutionalisation rates in this vulnerable population.

4 April 2023 in Osteoporosis International
Verified
Journal Article
Open access
PDF file
AKAliya A. Khan
Aliya A. Khan
HAHajar AbuAlrob
Hajar AbuAlrob
HAHatim Al-Alwani
Hatim Al-Alwani
DADalal Ali
Dalal Ali
KAKhulod Almonaei
Khulod Almonaei
PZPaul Zalzal
Paul Zalzal
Introduction Osteoporosis is a major disease state associated with significant morbidity, mortality, and health care costs. Less than half of the individuals sustaining a low energy hip fracture are diagnosed and treated for the underlying osteoporosis. Objective A multidisciplinary Canadian hip fracture working group has developed practical recommendations to meet Canadian quality indicators in post hip fracture care. Methods A comprehensive narrative review was conducted to identify and synthesize key articles on post hip fracture orthogeriatric care for each of the individual sections and develop recommendations. These recommendations are based on the best evidence available today. Conclusion Recommendations are anticipated to reduce recurrent fractures, improve mobility and healthcare outcomes post hip fracture, and reduce healthcare costs. Key messages to enhance postoperative care are also provided.

23 December 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
DADalal Ali
Dalal Ali
RMReza D Mirza
Reza D Mirza
FAFarah Alsarraf
Farah Alsarraf
SHSalma Hussein
Salma Hussein
HAHajar Abu Alrob
Hajar Abu Alrob
Gordon GuyattGordon Guyatt
Gordon Guyatt
Context: Understanding the effects of burosumab compared to conventional therapy or no treatment on patient-important outcomes in adults with X-linked hypophosphatemia (XLH) is essential to guide evidence-based treatment recommendations. Objective: To examine the highest certainty evidence addressing the management of XLH in adults to inform treatment recommendations. Methods: We searched Embase, MEDLINE, Web of Science, and Cochrane Central up to May 2023. Eligible studies included randomized controlled trials (RCTs) and observational studies of individuals aged 18+ with clinically or genetically confirmed XLH. Manuscripts comparing burosumab to no treatment or conventional therapy (phosphate and active vitamin D) and conventional therapy to no treatment were included. Two reviewers independently determined eligibility, extracted data, and assessed risk of bias (RoB). GRADE methodology was used to assess evidence certainty. Results: We screened 4114 records, after removing duplicates, and assessed 254 full texts. One RCT and 2 observational studies were eligible. The RCT of burosumab vs no treatment had low RoB. Burosumab probably improves pain from fracture/pseudofracture healing (moderate certainty) but has little or no impact on direct pain measures (moderate certainty). Burosumab may reduce the need for parathyroidectomy (low certainty) but has little or no impact on fatigue (high certainty), stiffness (moderate certainty), and mobility (low certainty) over 24 weeks. Burosumab may increase dental abscess risk (low certainty). Indirect evidence comparing burosumab to conventional therapy provided low certainty regarding burosumab vs conventional therapy. Two observational studies on conventional therapy vs no treatment had high RoB and very low certainty regarding the impact of conventional therapy on patient-important outcomes. Conclusion: No formal comparisons between burosumab and conventional therapy in adults exist. Evidence for conventional therapy vs no treatment is very uncertain. Our review highlights the need for more data on the long-term effects of burosumab and conventional therapy on patient-important outcomes in adult patients with XLH.